<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047772</url>
  </required_header>
  <id_info>
    <org_study_id>2016-807-10.1</org_study_id>
    <nct_id>NCT03047772</nct_id>
  </id_info>
  <brief_title>Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients</brief_title>
  <acronym>TEAM-AMI</acronym>
  <official_title>The Randomized Double-blind Placebo-Controlled Multi-center Clinical Trial of Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in Acute Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuejin Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of current stem cell transplantation therapy for myocardial infarction is limited
      by low survival rate for stem cell. The purpose of this study is to test whether intensive
      Atorvastatin therapy can improve the outcome of patients with impaired left ventricle
      function after acute myocardial infarction who underwent intracoronary transfer of autologous
      bone marrow mesenchymal stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major challenge to a successful stem cell therapy for myocardial infarction is the low
      survival rate of implanted cells in the damaged tissue. Atorvastatin, an HMG-CoA reductase
      inhibitor, has multiple biological activities independent of cholesterol-lowering action.This
      study is performed to find out more information about the strategy with Atorvastatin therapy
      to improve the survival of implanted cells, autologous bone marrow mesenchymal stem cells
      transplantation. Patients between 30 and 75 years of age who receive autologous bone marrow
      mesenchymal stem cells transplant may be eligible for this study. These patients receive
      autologous bone marrow mesenchymal stem cells transplantation intracoronary undergoing
      Percutaneous Coronary Intervention with regular or high dose of Atorvastatin treatment. The
      objective evaluations will be performed at baseline and during 12 months follow-up.

      Heart function tests may include the following:

      Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on
      the chest transmit information from the heart to a machine.

      Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the
      heart and examine the function of the heart chambers and valves.

      Gated acquisition scan is a nuclear medicine test that uses a small amount of radioactive
      chemical injected into a vein. A special scanner creates an image of the heart for examining
      the beating motion of the muscle.

      MRI evaluates function of the heart chambers the beating motion of the muscle.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction from baseline to 12 months'</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in left ventricular ejection fraction from baseline to 12 months' by MRI</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Phase A: Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin routine dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + low dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + middle dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin routine dose + high dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin routine dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin routine dose+ Optimal dose BMMSC Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Intensive Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin Intensive dose + placebo transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Routine dose of Atorvastatin therapy</description>
    <arm_group_label>Phase A: Atorvastatin</arm_group_label>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
    <arm_group_label>Phase B: Atorvastatin</arm_group_label>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Atorvastatin</intervention_name>
    <description>Intensive dose of Atorvastatin therapy</description>
    <arm_group_label>Phase B: Intensive Atorvastatin</arm_group_label>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose BMMSC</intervention_name>
    <description>Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: Low dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Middle dose BMMSC</intervention_name>
    <description>Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: Middle dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose BMMSC</intervention_name>
    <description>High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase A: High dose BMMSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplantation</intervention_name>
    <description>Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation</description>
    <arm_group_label>Phase B: Atorvastatin+Transplantation</arm_group_label>
    <arm_group_label>Phase B: Intensive Atorvastatin+Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with the first time ST-elevation myocardial infarction (STEMI).

          2. Patients after undergoing PCI 2 to 5 days.

          3. Patients without PCI but emergency coronary angiography shows the criminal coronary
             artery recanalized.

          4. Left ventricular infarction area seriously hypokinesis or no movement

          5. Left ventricular ejection fraction &lt;=45% based on coronary angiography or
             echocardiography.

        Exclusion Criteria:

        Any one of the following exclusion criteria is sufficient to disqualify a patient from the
        study.

          1. Patients without emergency PCI and the criminal coronary artery fail to be
             recanalized.

          2. Patients with non-ST-elevation myocardial infarction.

          3. Patients with normal left ventricular function.

          4. Patients with mechanical complications of myocardial infarction.

          5. Patients with a malignant tumor.

          6. Patients with infection disease.

          7. Less than 6 months since last episode of stroke.

          8. Patients with hematological disease (leukemia, myeloproliferative disease, or
             myelodysplastic syndromes).

          9. ALT (GPT) exceeding 100 IU/L.

         10. Leukocytes less than 4,000/µL or exceeding 10,000/µL.

         11. Platelets less than 100,000/µL.

         12. Hemoglobin less than 10 g/dL.

         13. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming
             pregnant before the end of the study period.

         14. Any other reason that the Clinical Supervisors or Clinical Researchers may have for
             considering a case unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haiyan Qian, Doctor</last_name>
    <phone>861068314466</phone>
    <email>ahqhy712@163.com</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yuejin Yang</investigator_full_name>
    <investigator_title>Vice Dean of Fuwai hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

